FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313389849> ?p ?o ?g. }

• W4313389849 endingPage "37" @default.
• W4313389849 startingPage "32" @default.
• W4313389849 abstract "Evaluation of the reasons for discontinuation of therapy with Janus kinase inhibitors (JAKi) may provide a clue to their more effective use. Objective : to analyze the survival of tofacitinib (TOFA) therapy and the reasons for its discontinuation in rheumatoid arthritis (RA) in real clinical practice. Patients and methods . The study included 30 adult patients with RA hospitalized to the V.A. Nasonova Research Institute of Rheumatology from 2018 to 2020 for the biologic disease modifying antirheumatic drugs (bDMARDs) or JAKi treatment. Patients were followed up for 3 years or until treatment with TOFA was discontinued, whichever occurred first. Results and discussion . TOFA was prescribed as the first line therapy in 3 patients. In all these patients, the drug was discontinued for the following reasons: insufficient efficacy (IE) after 2 full years of treatment; adverse reaction (AR); administrative reasons (AdR), i.e. the inability to continue therapy due to the lack of drug supply at the place of residence. 11 patients received TOFA as the second line therapy, in 8 of them the treatment was interrupted: in 4 due to IE, in 3 due to AR (skin allergy) and in 1 due to AdR one year after its initiation. TOFA was prescribed as a third line therapy in 9 patients, in 2 of them the drug was discontinued due to IE and in 3 due to AR (allergic dermatitis in 2, dyspepsia in 1). Another 1 patient refused treatment due to a planned pregnancy. 6 patients received TOFA as the fourth line therapy, 5 of them (83.3%) continued to receive it for more than 3 years. In 1 patient, TOFA was discontinued after 1 month due to the dry cough and shortness of breath onset. In another 1 patient who was prescribed TOFA as the fifth line therapy, treatment was discontinued due to AR (recurrent Herpes zoster). Conclusion . As the results of the study show, no relationship was found between the incidence of AR or IE and clinical and demographic indicators, as well as the frequency of TOFA withdrawal and the line of therapy. At the same time, the shortest duration of retention on TOFA therapy was noted when it was prescribed as a first-line drug." @default.
• W4313389849 created "2023-01-06" @default.
• W4313389849 creator A5025976331 @default.
• W4313389849 creator A5039791259 @default.
• W4313389849 creator A5090579529 @default.
• W4313389849 date "2022-12-17" @default.
• W4313389849 modified "2023-10-14" @default.
• W4313389849 title "Retention on tofacitinib therapy in patients with rheumatoid arthritis (real clinical practice data)" @default.
• W4313389849 cites W1974321634 @default.
• W4313389849 cites W1990105300 @default.
• W4313389849 cites W2014330392 @default.
• W4313389849 cites W2035320881 @default.
• W4313389849 cites W2038992287 @default.
• W4313389849 cites W2046744512 @default.
• W4313389849 cites W2063671947 @default.
• W4313389849 cites W2069302785 @default.
• W4313389849 cites W2101217991 @default.
• W4313389849 cites W2120393706 @default.
• W4313389849 cites W2129948300 @default.
• W4313389849 cites W2142004396 @default.
• W4313389849 cites W2149447280 @default.
• W4313389849 cites W2153414586 @default.
• W4313389849 cites W2164858045 @default.
• W4313389849 cites W2265836205 @default.
• W4313389849 cites W2626892937 @default.
• W4313389849 cites W2892263842 @default.
• W4313389849 cites W2926455583 @default.
• W4313389849 cites W2927614515 @default.
• W4313389849 cites W3010831470 @default.
• W4313389849 cites W3021665373 @default.
• W4313389849 cites W3040340304 @default.
• W4313389849 cites W3048591827 @default.
• W4313389849 cites W4212908502 @default.
• W4313389849 cites W4220675257 @default.
• W4313389849 doi "https://doi.org/10.14412/1996-7012-2022-6-32-37" @default.
• W4313389849 hasPublicationYear "2022" @default.
• W4313389849 type Work @default.
• W4313389849 citedByCount "0" @default.
• W4313389849 crossrefType "journal-article" @default.
• W4313389849 hasAuthorship W4313389849A5025976331 @default.
• W4313389849 hasAuthorship W4313389849A5039791259 @default.
• W4313389849 hasAuthorship W4313389849A5090579529 @default.
• W4313389849 hasBestOaLocation W43133898491 @default.
• W4313389849 hasConcept C126322002 @default.
• W4313389849 hasConcept C197934379 @default.
• W4313389849 hasConcept C2776233030 @default.
• W4313389849 hasConcept C2777575956 @default.
• W4313389849 hasConcept C2778715236 @default.
• W4313389849 hasConcept C2778886723 @default.
• W4313389849 hasConcept C71924100 @default.
• W4313389849 hasConceptScore W4313389849C126322002 @default.
• W4313389849 hasConceptScore W4313389849C197934379 @default.
• W4313389849 hasConceptScore W4313389849C2776233030 @default.
• W4313389849 hasConceptScore W4313389849C2777575956 @default.
• W4313389849 hasConceptScore W4313389849C2778715236 @default.
• W4313389849 hasConceptScore W4313389849C2778886723 @default.
• W4313389849 hasConceptScore W4313389849C71924100 @default.
• W4313389849 hasIssue "6" @default.
• W4313389849 hasLocation W43133898491 @default.
• W4313389849 hasOpenAccess W4313389849 @default.
• W4313389849 hasPrimaryLocation W43133898491 @default.
• W4313389849 hasRelatedWork W2606332666 @default.
• W4313389849 hasRelatedWork W2755978387 @default.
• W4313389849 hasRelatedWork W2887641776 @default.
• W4313389849 hasRelatedWork W2916556513 @default.
• W4313389849 hasRelatedWork W2967962363 @default.
• W4313389849 hasRelatedWork W3006153447 @default.
• W4313389849 hasRelatedWork W3085086630 @default.
• W4313389849 hasRelatedWork W4226373090 @default.
• W4313389849 hasRelatedWork W4307232541 @default.
• W4313389849 hasRelatedWork W4367721094 @default.
• W4313389849 hasVolume "16" @default.
• W4313389849 isParatext "false" @default.
• W4313389849 isRetracted "false" @default.
• W4313389849 workType "article" @default.